Purpose
To evaluate the intraocular pressure (IOP)-lowering effect of travoprost in normal-tension glaucoma (NTG) over a 12-month
follow-up.
Methods
Forty-five eyes of 45 patients with unilateral NTG were treated with travoprost (0.004%) once a day for 12 months. Mean IOP
and the IOP reduction from baseline were assessed at 0.5, 1, 3, 6, 9, and 12 months after the initiation of the treatment.
Adverse ocular event frequency and the frequency of discontinuation of treatment due to adverse events were evaluated.
Results
Mean IOP during 12 months of travoprost treatment ranged from 11.17 to 11.82 mmHg, and the mean IOP reduction in relation
to baseline IOP from −2.71 to −3.71 mmHg (−18.3% to −25.1%). Mean IOP and IOP changes in the travoprost-treated and control
groups were significantly different at every follow-up (P < 0.05 in each case). Both the magnitude (r = 0.6992) and percentage (r = 0.5464) of IOP reductions correlated positively with baseline IOP values. Ocular adverse events were usually mild to moderate
and resolved without treatment.
Conclusions
Travoprost was well tolerated and significantly reduced IOP in NTG patients. In addition, initial IOP reductions were maintained
throughout follow-up. Travoprost was found to be more effective in patients with greater baseline IOP.
Key Words adverse event - intraocular pressure - normal tension glaucoma - travoprost